José Carlos Nicolau

Author

José Carlos Nicolau

Also Known As

Alistair D. Nichol, Athanasios J. Manolis, Berger, Jeffrey S, Bryan J. McVerry, C. Juan José, C. Nicolau José, D Keith Edmonds, Gilmar Reis, J C Nicolau, J NICOLAU

686

Publications

44.5K

Citations

H-Index

183

Concepts

All Affiliations

Universidade de São Paulo Hospital das Clínicas da Faculdade de Medicina da Universidade de São Paulo Brigham and Women's Hospital Harvard University Clinical Research Institute

About

José Carlos Nicolau is an author at Universidade de São Paulo specializing in medicine, cardiovascular disease, and cardiology.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	40	86	10.2K
2	Health Sciences	7	7	529
3	Engineering	3	3	286
4	Natural Sciences	2	2	25
5	Language Studies	1	1	173

José Carlos Nicolau

225

Publications

40.8K

Citations

H-Index

Page 1

	Year	Citations
Antiinflammatory Therapy with Canakinumab for Atherosclerotic Disease Paul M. Ridker, Tom Thurén, Jean MacFadyen, New England Journal of Medicine	2017	8.7K
Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction John J.V. McMurray, Scott D. Solomon, Silvio E. Inzucchi, New England Journal of Medicine	2019	6.4K
Long-Term Use of Ticagrelor in Patients with Prior Myocardial Infarction Marc P. Bonaca, Deepak L. Bhatt, Marc Cohen, New England Journal of Medicine	2015	1.9K
Effect of interleukin-1β inhibition with canakinumab on incident lung cancer in patients with atherosclerosis: exploratory results from a randomised, double-blind, placebo-controlled trial Paul M. Ridker, Jean MacFadyen, Tom Thurén, The Lancet InflammationAllergyLung InflammationMedicineMetronomic Therapy	2017	1.3K
Vorapaxar in the Secondary Prevention of Atherothrombotic Events David A. Morrow, Eugene Braunwald, Marc P. Bonaca, New England Journal of Medicine	2012	927
Myocardial Viability and Survival in Ischemic Left Ventricular Dysfunction Robert O. Bonow, Gerald Maurer, Kerry L. Lee, New England Journal of Medicine	2011	869
Prasugrel versus Clopidogrel for Acute Coronary Syndromes without Revascularization Matthew T. Roe, Paul W. Armstrong, Keith A.A. Fox, New England Journal of Medicine	2012	859
Rivaroxaban with or without aspirin in patients with stable peripheral or carotid artery disease: an international, randomised, double-blind, placebo-controlled trial Sonia S. Anand, Jackie Bosch, John W. Eikelboom, The Lancet ThrombosisCardiovascular DiseaseStrokeMedicinePlacebo-controlled Trial	2017	855
Relationship of C-reactive protein reduction to cardiovascular event reduction following treatment with canakinumab: a secondary analysis from the CANTOS randomised controlled trial Paul M. Ridker, Jean MacFadyen, Peter Libby, The Lancet Cardiovascular ToxicityC-reactive Protein ReductionCardiovascular DiseaseCardiovascular PharmacologyEvent Reduction	2017	847
Evacetrapib and Cardiovascular Outcomes in High-Risk Vascular Disease A. Michael Lincoff, Stephen J. Nicholls, Jeffrey Riesmeyer, New England Journal of Medicine	2017	768

Page 1